Masimo’s revolutionary SET® pulse oximetry has been shown in more than 100 independent and objective studies to outperform other pulse oximetry technologies – even before the revisions that achieved ...
New Neonatal Study Adds to Body of Clinical Evidence Demonstrating Masimo SET ® Pulse Oximetry’s Unique Ability to Improve Care NEUCHATEL, Switzerland--(BUSINESS WIRE)--Masimo (NASDAQ: MASI) provides ...
About a year after beginning its full market launch, Masimo’s W1 smartwatch can now be used as a medical device in the U.S. The wearable device has earned FDA clearance for its medical applications, ...
The Automation of Neonatal Critical Congenital Heart Disease (CCHD) Screening Across More Than 370 Healthcare Facilities Is Expected to Improve the Process of Screening More Than 550,000 Newborns ...
Masimo Corp. ((MASI)) announced an update on their ongoing clinical study. Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to ...
Masimo (NASDAQ: MASI) is a global medical technology company that develops and produces a wide array of industry-leading monitoring technologies, including innovative measurements, sensors, patient ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback